Markets:

Overview

News

Currencies

International

Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

15.82 -0.66 (-4.00%)

Official Closing Price Updated: 7:00 PM EST, Mar 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

36 37 Next >

Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last ↗

Today 0:38 EST

The warnings involve compounded versions of Semaglutide, Tirzepatide and Liraglutide, the active ingredients in Wegovy, Ozempic and Mounjaro.

Via Stocktwits

Topics Lawsuit

Hims & Hers Finds A GLP-1 Hedge? HIMS Stock Rallies As RFK Jr. Signals Peptide Clearances ↗

March 03, 2026

The Futurum Group CEO Daniel Newman said Hims is the “most likely public company play” for peptides at scale.

Via Stocktwits

Topics Earnings Supply Chain

What's Behind The Jump In Hims & Hers Health Stock? ↗

March 02, 2026

Shares of Hims & Hers Health, Inc. (NASDAQ: HIMS) are rising Monday after Secretary of Health and Human Services Robert F. Kennedy Jr. said on the Joe Rogan podcast that several peptide compounds, a...

Via Benzinga

Unexpected Stock Picks and Looking to the Future ↗

March 02, 2026

Why does the shortest month of the year sometimes feel like the longest?

Via The Motley Fool

Hims & Hers Health Inc (NYSE:HIMS) Stock Falls on Weak Q1 2026 Revenue Guidance Despite Q4 Earnings Beat ↗

February 23, 2026

Via Chartmill

HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? ↗

February 11, 2026

Via Stocktwits

Why I'm Not Worried About Novo Nordisk Stock ↗

March 02, 2026

The stock is down big of late, but the business is by no means doomed.

Via The Motley Fool

Topics Intellectual Property

MarketBeat Week in Review – 02/23 - 02/27 ↗

February 28, 2026

Sometimes the best offense is a good defense. That’s what investors seem to be feeling. Technology stocks continue to be under pressure, and that money is flowing into traditionally defensive assets...

Via MarketBeat

PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know

February 27, 2026

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key...

Via StockStory

Topics Economy Government Stocks

Down 70% Over the Past Year, Can Hims & Hers Health Stock Bounce Back? ↗

February 27, 2026

The company is looking toward international markets to boost its growth.

Via The Motley Fool

Topics Intellectual Property Lawsuit

Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making ↗

February 27, 2026

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising.

Via The Motley Fool

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026

February 26, 2026

As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗

February 26, 2026

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.

Via The Motley Fool

HIMS Stock Plummets After Wall Street Downgrade, Price Target Cuts Following 'Disappointing' Q4 Report ↗

February 24, 2026

HIMS stock is currently trading at levels last seen in September 2024 and has fallen over 50% year-to-date.

Via Stocktwits

Topics Artificial Intelligence

Hims & Hers Health (HIMS): Decoding the Q4 Earnings Beat vs. the SEC GLP-1 Investigation

February 24, 2026

As of February 24, 2026, the market narrative surrounding Hims & Hers Health (NYSE: HIMS) has become a stark "tale of two tapes." On one hand, the digital health disruptor recently reported a robust Q4...

Via Finterra

Topics Earnings Economy Initial Public Offering

Nasdaq, S&P 500 Futures Steady After AI Fears Roil Tech: Why IBM, NVDA, NFLX, HIMS, PFE Are On Traders' Radar Today ↗

February 24, 2026

Data from Stocktwits indicated retail sentiment on SPY and QQQ remained ‘bearish’ on Stocktwits.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

HIMS Stock Slumps Nearly 10% After-Hours: How CEO Dudum Plans To Offset GLP-1 Risk ↗

February 23, 2026

The company reiterated its longer-term targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.

Via Stocktwits

Topics Earnings

Hims & Hers (HIMS) Earnings Call Transcript ↗

February 23, 2026

Hims & Hers (HIMS) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Hims & Hers Health Reports Mixed Q4 Earnings, Subscribers Cross 2.5 Million ↗

February 23, 2026

Hims & Hers Health Inc (NYSE:HIMS) reports financial results for the fourth quarter after the market close on Monday.

Via Benzinga

Hims & Hers Health’s (NYSE:HIMS) Q4 CY2025 Earnings Results: Revenue In Line With Expectations

February 23, 2026

Telehealth company Hims & Hers Health (NYSE:HIMS) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 28.4% year on year to $617.8 million. On the other hand, next quarter’s revenue...

Via StockStory

High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026

February 23, 2026

As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the...

Via Finterra

Topics Artificial Intelligence Intellectual Property Lawsuit

HIMS Stock Short Interest At Record Levels Ahead Of Q4 Earnings: What Are Bears Betting Against? ↗

February 23, 2026

Short interest climbed from about 18.5% on Jan.1 to 33.7% by Monday.

Via Stocktwits

What To Expect From Hims & Hers Health’s (HIMS) Q4 Earnings

February 21, 2026

Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market close. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence Economy World Trade

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside ↗

February 21, 2026

Via MarketBeat

Hims & Hers HUGE Acquisition News! ↗

February 19, 2026

Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.

Via The Motley Fool

Hims & Hers Health Makes Australia, Japan Foray With $1.15 Billion Eucalyptus Acquisition ↗

February 19, 2026

Hims & Hers Health, Inc. (HIMS) announced on Thursday that it has signed a definitive agreement to acquire Eucalyptus in a deal valued at up to $1.15 billion.

Via Stocktwits

2 Profitable Stocks on Our Watchlist and 1 We Ignore

February 16, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

February 13, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

Via StockStory

Topics Economy

Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗

February 10, 2026

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

Via Stocktwits

The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS)

February 10, 2026

Today is February 10, 2026. The telehealth landscape stands at a historic inflection point, and no company better embodies this volatility than Hims & Hers Health, Inc. (NYSE: HIMS). After a meteoric...

Via Finterra

Topics Artificial Intelligence Intellectual Property Lawsuit

< Previous 1 2 3 4 5 6 7 8 9

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.